IGC vs. SLN, AMYT, BMY, OGN, GPH, ARTL, AURA, PHAR, ORPH, and AMPH
Should you be buying India Capital Growth stock or one of its competitors? The main competitors of India Capital Growth include Silence Therapeutics (SLN), Amryt Pharma (AMYT), Bloomsbury Publishing (BMY), Origin Enterprises (OGN), Global Ports (GPH), Alpha Real Trust (ARTL), Aura Energy (AURA), Pharos Energy (PHAR), Open Orphan (ORPH), and Aggregated Micro Power (AMPH). These companies are all part of the "pharmaceutical products" industry.
India Capital Growth vs. Its Competitors
Silence Therapeutics (LON:SLN) and India Capital Growth (LON:IGC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
India Capital Growth has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than India Capital Growth, indicating that it is currently the more affordable of the two stocks.
Silence Therapeutics received 185 more outperform votes than India Capital Growth when rated by MarketBeat users. Likewise, 68.81% of users gave Silence Therapeutics an outperform vote while only 56.25% of users gave India Capital Growth an outperform vote.
In the previous week, India Capital Growth had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for India Capital Growth and 1 mentions for Silence Therapeutics. India Capital Growth's average media sentiment score of 0.38 beat Silence Therapeutics' score of 0.00 indicating that India Capital Growth is being referred to more favorably in the news media.
India Capital Growth has a net margin of 93.35% compared to Silence Therapeutics' net margin of 0.00%. India Capital Growth's return on equity of 25.12% beat Silence Therapeutics' return on equity.
24.3% of India Capital Growth shares are owned by institutional investors. 0.2% of India Capital Growth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
India Capital Growth beats Silence Therapeutics on 10 of the 12 factors compared between the two stocks.
Get India Capital Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
India Capital Growth Competitors List
Related Companies and Tools
This page (LON:IGC) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy IGC Stock Free IGC Stock Alerts